- Home
- BFST vs ABVX Comparison
BFST vs ABVX Comparison
Compare BFST & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- ABVX
- Stock Information
- Founded
- BFST 2006
- ABVX 2013
- Country
- BFST United States
- ABVX France
- Employees
- BFST N/A
- ABVX N/A
- Industry
- BFST Major Banks
- ABVX
- Sector
- BFST Finance
- ABVX
- Exchange
- BFST Nasdaq
- ABVX Nasdaq
- Market Cap
- BFST 838.4M
- ABVX 722.3M
- IPO Year
- BFST 2018
- ABVX N/A
- Fundamental
- Price
- BFST $26.02
- ABVX $6.37
- Analyst Decision
- BFST Buy
- ABVX Strong Buy
- Analyst Count
- BFST 2
- ABVX 7
- Target Price
- BFST $28.00
- ABVX $37.86
- AVG Volume (30 Days)
- BFST 111.3K
- ABVX 214.7K
- Earning Date
- BFST 01-23-2025
- ABVX 09-09-2024
- Dividend Yield
- BFST 2.15%
- ABVX N/A
- EPS Growth
- BFST N/A
- ABVX N/A
- EPS
- BFST 2.32
- ABVX N/A
- Revenue
- BFST $249,883,000.00
- ABVX $9,676,417.00
- Revenue This Year
- BFST N/A
- ABVX $31.67
- Revenue Next Year
- BFST $18.08
- ABVX $759.77
- P/E Ratio
- BFST $11.02
- ABVX N/A
- Revenue Growth
- BFST 1.14
- ABVX 100.87
- 52 Week Low
- BFST $18.97
- ABVX $5.54
- 52 Week High
- BFST $30.30
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- BFST 52.92
- ABVX 35.26
- Support Level
- BFST $22.95
- ABVX $6.01
- Resistance Level
- BFST $25.56
- ABVX $6.46
- Average True Range (ATR)
- BFST 0.67
- ABVX 0.46
- MACD
- BFST 0.20
- ABVX -0.01
- Stochastic Oscillator
- BFST 94.46
- ABVX 41.71
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a United States-based bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.